The press release mentioned a reduction in A1C of about 1%. It didn't sound all that special to me at the time, because I didn't know anything behind it. This is the case: These studies are on people that are on the accepted treatments, but the non-placebo people get Exenatide ALSO. Keep this in mind. At the start of the studies the baseline for A1C was 8.4 to 8.6%. But at the end of the studies placebo people (using only the accepted treatments) hadn't changed more than 0.1%, but those on Exenatide (10ug at breakfast and dinner) were down to 7.2 to 7.4%. The GOAL is 7%. Normal is 6%. That IS extrodinary. 40 to 50% of the people in the studies on the 10 ug dose met or beat the goal.
As for the 8 lb. weight loss: We were informed (I sure didn't know it) that people on insulin tend to GAIN weight. The addition of Exenatide changed that, and people LOST weight, on average. That, too, is extrodinary.
At the end of the 6 month studies 80% of the participants STAYED ON THE MEDICINE by choice. Many on the placebo voluntarily went on Exenatide and by the end of another six months were in the same place as those that went from 5 ug to 10 ug and those that were on 10 ug to start with (at least, for A1C levels. When it came to weight loss, those on 10 ug from the start had a good lead).